Rob Maier examines the Federal Circuit's reversal restoring patent eligibility for engineered host cells in gene therapy, reinforcing that recombinant compositions assembled through human intervention qualify as patentable subject matter even when their underlying sequences occur naturally.

To read the complete article in the New York Law Journal, please click the title:

Splicing Patent Eligibility: The Federal Circuit Restores 101 Eligibility for Engineered Cells in 'REGENXBIO v. Sarepta'